Zander Therapeutics, Inc
CIK 0001718644
Revenue (TTM)
—
Q1 Sep 2019
Net Income (TTM)
−$3.64M
+114.1% YoY
Q1 Sep 2019
EPS Diluted (TTM)
—
Q1 Sep 2019
Gross Margin
—
Q1 Sep 2019
Operating Margin
—
Q1 Sep 2019
Net Margin
—
Q1 Sep 2019
Free Cash Flow (TTM)
—
Q1 Sep 2019
Cash
$4.52K
Q1 Sep 2019
Total Debt
—
Q1 Sep 2019
Shares Outstanding
6.58M sh
Q1 Sep 2019
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.